phenylalanyl-leucyl-phenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide has been researched along with Cognitive Dysfunction in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Meng, Y; Shi, B; Sun, S | 1 |
1 other study(ies) available for phenylalanyl-leucyl-phenylalanyl-glutaminyl-prolyl-glutaminyl-arginyl-phenylalaninamide and Cognitive Dysfunction
| Article | Year |
|---|---|
Elevated Serum Neuropeptide FF Levels Are Associated with Cognitive Decline in Patients with Spinal Cord Injury.
Topics: Biomarkers; Case-Control Studies; Cognitive Dysfunction; Female; Follow-Up Studies; Humans; Male; Middle Aged; Oligopeptides; Prognosis; Prospective Studies; Spinal Cord Injuries | 2021 |